Agenus Inc. stocks have been trading up by 115.37 percent, driven mainly by strong immunotherapy trial progress and partnership momentum.
Click Here for a Millionaire's POV on Trading AGEN
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways Traders Need To Know
- Three-year Phase 1b data show 21.2-month median overall survival and 33% three-year OS in tough colorectal cancer, well above historical later-line outcomes.
- The botensilimab plus balstilimab combo delivered durable responses, a treatment-free subset, and no new safety signals or treatment-related deaths.
- AGEN reported a survival plateau beyond two years, hinting at long-term benefit for a portion of patients.
- Results reinforce and de-risk the ongoing Phase 3 BATTMAN trial in microsatellite-stable metastatic colorectal cancer.
- The same Phase 1b data set will be showcased at ESMO GI Cancers Congress 2026, adding a clear catalyst on the calendar.
Live Update At 10:03:52 EDT: On Monday, July 13, 2026 Agenus Inc. stock [NASDAQ: AGEN] is trending up by 115.37%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
AGEN has been trading like a biotech rocket. On 2026/07/13, the stock ripped from a $5.42 open to a $7.27 high and closed at $7.24. That move followed days of grinding higher from the low-$3s, turning what was a slow uptrend into a full-on momentum breakout.
Intraday, AGEN showed classic high-volume squeeze behavior. Pre-market trade built from roughly $3.30–$4.00, then once regular hours opened, buyers stepped in hard. The stock ran from sub-$5 at 09:30 to over $7 by 10:00, with only shallow pullbacks. For short-term traders, that pattern screams “trend day” with dip-buy opportunities near intraday VWAP and prior consolidation zones.
More Breaking News
- CAG Rallies As Conagra Wins Index Spot Amid Dividend Jitters
- RAM ETF Slides After Parabolic Run As Volatility Spikes
- NOK Stock Slides As ADR Weakness Puts Pressure On Bulls
- PMA Stock Jumps As Traders Target Volatile Spike
Under the hood, the numbers show a typical high-risk biotech profile. AGEN generated about $114.2M in revenue over the trailing period, but its current ratio of 0.4 and quick ratio of 0.2 flag tight liquidity. Free cash flow is negative at roughly -$35.9M for the quarter, and working capital stands deep in the red. The low price-to-sales near 1.2 and unusual P/E reflect one-off gains and a stressed balance sheet. Translation for traders: AGEN is a story and catalyst name, not a fundamentals-first safe haven.
Why Traders Are Watching AGEN’s Cancer Data
AGEN is back on radar because of real clinical signal, not just message-board hype. The company reported mature three-year Phase 1b data for its botensilimab plus balstilimab combo in refractory microsatellite-stable metastatic colorectal cancer without active liver metastases. Median overall survival hit 21.2 months, with a 33% three-year overall survival rate. That roughly doubles what later-line patients usually see.
For a hard-to-treat population like MSS colorectal cancer, that kind of delta matters. AGEN is showing not just incremental improvement, but a step-change versus historical benchmarks. Traders know that when survival curves move this much, the market tends to re-rate the pipeline.
The details matter here. AGEN highlighted durable responses, including a subset of patients who are off all systemic therapy. That “treatment-free” subset is what big pharma looks for when it scouts next-generation immuno-oncology assets. At the same time, AGEN reported no new safety signals and no treatment-related deaths. For a combo therapy, that safety profile is key; toxicity kills commercial stories even when the efficacy looks great.
Perhaps the most interesting signal for AGEN is the reported survival plateau beyond two years. When survival curves flatten like that, it often means a group of patients is benefiting long term. Traders should read that as early validation of the mechanism and a stronger bull case around the ongoing Phase 3 BATTMAN trial. Add the upcoming ESMO GI Cancers Congress 2026 presentation of the C-800-01 three-year data, and AGEN now has a visible conference catalyst that lines up with this momentum spike.
Conclusion
For active traders, AGEN checks several boxes at once: a clear catalyst, strong data, and a technical breakout that’s attracting volume. The Phase 1b botensilimab plus balstilimab data are still early-stage, but they meaningfully de-risk the BATTMAN Phase 3 program in MSS metastatic colorectal cancer and reset expectations for what this pipeline might be worth.
At the same time, the financials remind everyone this is still a classic high-risk biotech. AGEN carries negative free cash flow, a weak liquidity profile, and a balance sheet built around raising capital, not steady cash generation. That mix is exactly why the stock trades so sharply around news — the story is binary, and each data update can swing perceived survival odds for both patients and the company.
From a trading standpoint, the recent rip from the low-$3s to the mid-$7s shows what strong news plus tight floats and high short interest can do. Trend-followers will watch to see if AGEN holds higher lows above prior resistance near $5–$5.50, while short-biased traders will stalk a blow-off top or failed breakout. As Tim Sykes loves to say, “The market rewards prepared traders, not hopeful gamblers.” As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” AGEN is a prime example — understand the data, respect the volatility, and always trade a plan, not a story.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.